CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PD-MIND project aims to evaluate the cognitive effects of a specific nicotinic receptor agonist on patients with Parkinson's disease and mild cognitive impairment. It will involve a randomized clinical trial to assess improvements in cognition and related biomarkers.
Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease.
There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI).
There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition.
Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure.
Henc…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Exeter
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
SUS STAVANGER UNIVERSITETSSJUKEHUS STAVANGER UNIVERSITY HOSPITAL STAVANGER HOSPITAL TRUST
Norway, Stavanger
Type: Other
Activity type: Other
SME: No
Italy, Chieti
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
